Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9225
Title: Vasopressin receptor antagonism--a therapeutic option in heart failure and hypertension.
Austin Authors: Burrell, Louise M ;Risvanis, John;Johnston, Colin I;Naitoh, M;Balding, Leanne C
Affiliation: Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia
Issue Date: 1-Mar-2000
Publication information: Experimental Physiology; 85 Spec No(): 259S-265S
Abstract: The precise role of vasopressin in the pathophysiology of cardiovascular disease is controversial, but this peptide hormone is important for several reasons. Firstly, circulating concentrations of vasopressin are elevated in heart failure and some forms of hypertension. Secondly, there is evidence that vasopressin is synthesized not only in the hypophysial-pituitary axis but also in peripheral tissues including the heart where it acts as a paracrine hormone. Thirdly, vasopressin has vasoconstrictor, mitogenic, hyperplastic and renal fluid retaining properties which, by analogy with angiotensin II, may have deleterious effects when present in chronic excess. Finally, the availability of orally active non-peptide vasopressin receptor antagonists allows vasopressin receptor antagonism to be considered as a therapeutic option in cardiovascular disease.
Gov't Doc #: 10795930
URI: http://ahro.austin.org.au/austinjspui/handle/1/9225
URL: https://pubmed.ncbi.nlm.nih.gov/10795930
Type: Journal Article
Subjects: Antidiuretic Hormone Receptor Antagonists
Benzazepines.therapeutic use
Heart Failure.drug therapy.physiopathology
Humans
Hypertension.drug therapy.physiopathology
Morpholines.therapeutic use
Receptors, Vasopressin.physiology
Spiro Compounds.therapeutic use
Appears in Collections:Journal articles

Show full item record

Page view(s)

10
checked on Dec 2, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.